Login to Your Account

Pharma: Clinic Roundup

Tuesday, November 5, 2013
• Merck and Co. Inc., of Whitehouse Station, N.J., said that in a Phase III study, its vaccine for human papilloma virus (HPV), V503, prevented 97 percent of cervical, vaginal and vulvar pre-cancers caused by HPV types 31, 33, 45, 52 and 58.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription